FSS icon
  • WHY FSS?
    • About Us
    • Careers
  • SERVICES
    • Data Management
    • Biostatistics
    • Quality
  • OUTREACH
    • Patient
    • STEM
    • Inclusivity and Sustainability
    • Community
  • RESOURCES
    • FSS News
    • Case Studies
    • Projects
    • Publications
  • CONTACT US
NeoALTTO: European Journal of Cancer (EJC)

NeoALTTO: European Journal of Cancer (EJC)

by Robin McConnell | Jan 16, 2023 | NeoALTTO, Publications

Title of Publication Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer AUTHORS Paolo Nuciforo; John Townend; Martine J. Piccart; Shona Fielding; Panagiota Gkolfi, Sarra El-Abed; Evandro de Azambuja; Gustavo Werutsky;...
The Neo-ALTTO Trial: Pathological complete response after neoadjuvant anti-HER2 therapy

The Neo-ALTTO Trial: Pathological complete response after neoadjuvant anti-HER2 therapy

by Robin McConnell | Sep 1, 2014 | NeoALTTO, Publications

OVERVIEW Reported data for the prespecified secondary endpoints of event-free and overall survival, and assess the association between these outcomes and pathological complete response the the Neo-ALTTO trial. STUDY DETAILS The Neo-ALTTO (Neoadjuvant Lapatinib and/or...
The Neo-ALTTO Trial: Dual inhibition of HER2 in HER2-positive Breast Cancer

The Neo-ALTTO Trial: Dual inhibition of HER2 in HER2-positive Breast Cancer

by Emma Paterson | Feb 18, 2012 | NeoALTTO, Publications

OVERVIEW An argument that the two anti-HER2 agents, trastuzumab and lapatinib, given together would be better than single-agent therapy. STUDY DETAILS The Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study is a randomised, multicenter...

Recent Posts

  • Navigating the biopharma services landscape
  • ALEXANDRA | Journal of the American Medical Association (JAMA)
  • ALTTO | ESMO Open
  • APHINITY | Journal of Clinical Oncology
  • Keep CAALM and Carry On Doing Clinical Trials

Recent Comments

No comments to show.


Data Protection

EU Representative

Privacy

Cookies

CONTACT US
LinkedIn Logo

Frontier Science (Scotland) Ltd © 2022
Scottish Charity: SCO33112 | Scottish Company: SC220936

Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}